Skip to main content

Nanotherapeutics to Treat Antibiotic Resistant Gram-Negative Pneumonia Infections

Objective

The main objective of PneumoNP is the development of a theragnostic system for the treatment of lung Gram-negative bacterial infections. As a proof of concept PneumoNP will focus the attention on Klebsiella pneumoniae caused infections. A diagnostic kit will be developed to enable a rapid and precise identification of the bacteria strain causing the infection and avoid the use of wide spectrum antibiotics. For the treatment a nanotherapeutic based inhalable antibiotic will be developed. The therapeutic nanosystem will be based on a nanocarrier combined with an antimicrobial peptide. 3 different types of NCs will be tested with 2 AMPs to be able to obtain a novel effective inhalable antimicrobial NS. Nanotherapeutics offers many advantages in pulmonary drug-delivery, due to the huge surface area available in the lungs and their potential to achieve uniform distribution of drug dose among the alveoli. To improve this delivery to the lungs an aerosol system will also be developed. Due to the characteristics related to pulmonary delivery of NCs, topical and systemic bioavailabilities are envisaged. A diagnostic kit will be generated to monitor the efficacy and efficiency of the therapy. Once this treatment is proved to be effective, it could then be applied to any Gram-negative lung bacterial infection.
The number of antibiotic resistant bacteria strains is increasing rapidly, new types of therapy are urgently required to avoid the use of standard antibiotics. Gram-negative bacteria that cause pneumonia are one of the main sources of nosocomial infections, mainly in people with a weakened immune system. Apart from pneumonia they can cause bacteremia and other infections. Early detection of the infection source combined with the development of appropriate and effective NSs to treat multi-drug resistant (MDR) bacteria caused infections will definitely radically improve the healing process of patients and avoid complications for people in hospital.

Field of science

  • /natural sciences/biological sciences/microbiology/bacteriology
  • /medical and health sciences/basic medicine/immunology
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/drug resistance/multidrug resistance

Call for proposal

FP7-NMP-2013-LARGE-7
See other projects for this call

Funding Scheme

CP-IP - Large-scale integrating project

Coordinator

FUNDACION CIDETEC
Address
Paseo Miramon 196 Parque Tecnologico De Miramon
20014 San Sebastian
Spain
Activity type
Research Organisations
EU contribution
€ 896 660

Participants (10)

ADENIUM BIOTECH APS
Denmark
EU contribution
€ 416 300
Address
Ole Maaloesvej 3
2200 Kobenhavn
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE
Spain
EU contribution
€ 555 990,80
Address
Paseo Miramon 182, Parque Tecnologico De San Sebastian Edificio Empresarial C
20009 San Sebastian
Activity type
Research Organisations
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Netherlands
EU contribution
€ 975 861,20
Address
Dr Molewaterplein 40
3015 GD Rotterdam
Activity type
Higher or Secondary Education Establishments
EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH
Germany
EU contribution
€ 332 340
Address
Heinrich-hertz-allee 1
66386 St Ingbert
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
Germany
EU contribution
€ 511 251,25
Address
Hansastrasse 27C
80686 Munchen
Activity type
Research Organisations
INGENIATRICS TECNOLOGIAS SL
Spain
EU contribution
€ 454 658
Address
Calle Camino Mozarabe 41 Parque Industrial Parque Plata Camas
41900 Sevilla
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
PATHOFINDER BV
Netherlands
EU contribution
€ 497 681,60
Address
Randwycksingel 45
6229 EG Maastricht
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
SETLANCE SRL
Italy
EU contribution
€ 341 902,40
Address
Via Fiorentina 1
53100 Siena
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UMAPS COMMUNICATION SARL
France
EU contribution
€ 183 520
Address
Avenue De La Resistance 104 112
93100 Montreuil
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITEIT UTRECHT
Netherlands
EU contribution
€ 516 185,75
Address
Heidelberglaan 8
3584 CS Utrecht
Activity type
Higher or Secondary Education Establishments